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ticular, only 5 of the 19 sexuality/ED-specific measures
adequately covered the conceptual domains of interest
while only 8 of them had adequate evidence of reliability,
validity and responsiveness. CONCLUSION: Our review
underscores the need for a careful examination of pub-
lished psychometric properties of instruments that are be-
ing considered for use even when they are claimed to
have been developed for persons with ED and related
sexual disorders.
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As the female population continues to live longer past
menopause, healthcare providers need to establish a pro-
active approach to the management of the menopausal
population in order to reduce long-term healthcare ex-
penditures. OBJECTIVE: The purpose of this analysis is
to assess the cost-effectiveness of hormone replacement
therapy (HRT) in peri-menopausal women of Belgium
and the United Kingdom. METHODS: A Markov model
was constructed to model treatment pathways and out-
comes of two cohorts. The model compares the health
and economic outcomes of women from age 53 through
94 treated with HRT versus those not treated with HRT.
The following “health states” were considered in the
model: well, osteoporosis-related fractures, coronary
heart disease, stroke, Alzheimer’s disease, breast cancer,
diabetes and death. A clinical management analysis de-
termined health care utilization for each “health state”,
while published epidemiologic estimates from each coun-
try, incorporating relative risk ratios, incidence and mor-
tality rates for each “health state” were entered into the
model. A resource valuation using country-specific inpa-
tient and outpatient costs were calculated for each
“health state”. RESULTS: Cost-effectiveness was mea-
sured as the incremental cost-per-life-year gained and the
incremental cost per event avoided. Assuming full com-
pliance with treatment in the HRT cohorts, the results
for Belgium and the United Kingdom indicate significant
reductions in episodes of disease. Furthermore, lifetime
expected costs per patient in the treated cohort decreased
with age while the lifetime costs of the untreated cohort
increased with age. A Monte Carlo analysis tested the
sensitivity of the model results. CONCLUSIONS: Hor-
mone replacement therapy is a more cost-effective means
of disease prevention when compared to no treatment
and should be considered by healthcare providers in Bel-
gium and the United Kingdom in the health management
of peri-menopausal populations.
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Benign Prostatic Hyperplasia (BPH) is common among
males in the Veterans Administration (VA) population.
The quality of life of such patients can decline signifi-
cantly since symptoms may interrupt normal daytime ac-
tivities or sleep, create anxiety, or reduce perception of
general health. Though clinical practice guidelines for the
management of BPH have been established, little research
has been done to determine adherence to such guidelines.
OBJECTIVE: To determine the preferences of urologists
in the management of BPH in the VA population to as-
sess compliance with established guidelines. METHODS:
A self-administered mail survey was sent to about 300
urologists providing services to the VA population in ap-
proximately 145 VA medical centers across the US. The
survey contained simulated cases of BPH patients, to de-
termine urologists’ preferences for diagnostic tests and
treatments recommended in the management of BPH.
The survey also gathered information on frequency of
failed initiation therapy and demographic and practice
information. The survey was pilot tested for face and
content validity among 10 urology residents. Descriptive
statistics will be used to analyze the level of agreement
among respondent urologists for diagnostic procedures
and treatments recommended. Differences based on de-
mographic and practice characteristics will also be deter-
mined. Urologists’ preferences will also be compared
with clinical guidelines and responses of an expert panel.
Failure rates for initiation therapy will also be deter-
mined using descriptive statistics. Published cost data for
various diagnostic procedures will be used to estimate the
mean cost of diagnosing BPH in the VA population.
CONCLUSION: Study results will help us better under-
stand how BPH is managed in the VA population.
Economic & Outcomes Research Methodological 
Issues PMT
PMT1
THE VALUE OF OBSERVATIONAL DATASETS IN 
THE ECONOMIC EVALUATION OF 
PHARMACEUTICALS: UK OBSERVATIONS
Tolley K1, Pang F2, Brown M1
1Outcomes Research, Pfizer Central Research, Sandwich, Kent, 
UK; 2Centre for Health Economics, University of York, York, UK
OBJECTIVES: This research investigates the use of longi-
tudinal/cohort observational designs containing patient-
specific data for the economic evaluation of pharmaceuti-
cals in development or on the market, and appraises the
